Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Proof of Principle Program - Phase I

Université de Montréal

$160,000.00

Targeting the degradation of the cyclin-dependent kinase inhibitor p21 as a novel approach to cancer therapy

EF 2010-11

Résumé
The proliferation of cells is regulated by a complex network of biochemical reactions that ensure that each cell division step is performed correctly and in proper sequence. Among these reactions is the timed degradation of cellular regulatory proteins by an enzymatic system known as the ubiquitin-proteasome system. Accumulating evidence indicates that deregulation of the ubiquitin-proteasome system contributes to uncontrolled cell proliferation and genetic instability typical of cancer cells. Indeed, inhibition of the ubiquitin-proteasome system represents a novel and unique approach for the targeted therapy of cancer. The objective of our research is to identify small molecules able to inhibit the degradation of cell cycle inhibitors, and thus increase their expression, as a novel approach to stop the proliferation of cancer cells. Our long-term goal is to develop these small molecules into novel mechanism-based drugs for the targeted treatment of cancer.
Programme
Proof of Principle Program - Phase I
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
212876
Name
Meloche Sylvain
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Targeting the degradation of the cyclin-dependent kinase inhibitor p21 as a novel approach to cancer therapy
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Cancer; Cell Cycle; Cyclin-Dependent Kinase Inhibitors; Drug Development; Medicinal Chemistry; Ubiquitin-Proteasome System
Abstract
The proliferation of cells is regulated by a complex network of biochemical reactions that ensure that each cell division step is performed correctly and in proper sequence. Among these reactions is the timed degradation of cellular regulatory proteins by an enzymatic system known as the ubiquitin-proteasome system. Accumulating evidence indicates that deregulation of the ubiquitin-proteasome system contributes to uncontrolled cell proliferation and genetic instability typical of cancer cells. Indeed, inhibition of the ubiquitin-proteasome system represents a novel and unique approach for the targeted therapy of cancer. The objective of our research is to identify small molecules able to inhibit the degradation of cell cycle inhibitors, and thus increase their expression, as a novel approach to stop the proliferation of cancer cells. Our long-term goal is to develop these small molecules into novel mechanism-based drugs for the targeted treatment of cancer.
Competitiondate
201009
Approvedterm2
1 yr 0 mth
Pinamesdelim
Meloche, Sylvain
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~